Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex

Michael Shara, Anthony Kincaid, Aimee L. Limpach, Robert W. Sandstrom, Laura Barrett, Neil Norton, J. D. Bramble, Taharat Yasmin, Janet Tran, Archana Chatterjee, Manashi Bagchi, Debasis Bagchi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Chromium (III) is an essential micronutrient required for normal protein, fat and carbohydrate metabolism, as well as helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. A broad spectrum of research investigations including in vitro, in vivo and clinical studies demonstrated the beneficial effects of novel oxygen- coordinated niacin-bound chromium (III) complex (NBC) in promoting glucose-insulin sensitivity, lipid profile, cardioprotective ability and lean body mass. This study examined the long-term safety of NBC by orally administering either 0 or 25 ppm or the human equivalency dose of 1000 μg elemental chromium (III) as NBC per day for 52 consecutive weeks to male and female Sprague-Dawley rats. Animals of each group and each gender were sacrificed on 26, 39, or 52 weeks of treatment. Body weight, physical and ocular health, feed and water intake, selected organ weights as such and as a percentage of liver and brain weight, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluations were conducted. At 26, 39, or 52 weeks of treatment, body weight gain was significantly reduced by 7.7%, 8.1% and 14.9% in male rats, and 5.5%, 11.4% and 9.6% in female rats, respectively, in the NBC treatment groups. No significant changes were observed in hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluation between control and NBC groups at these time points. These findings, thus far, are in agreement with the subchronic studies in terms of the safety of NBC.

Original languageEnglish
Pages (from-to)1059-1069
Number of pages11
JournalJournal of Inorganic Biochemistry
Volume101
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Niacin
Chromium
Rats
Clinical Chemistry
DNA Fragmentation
Hematology
Oxygen
Lipids
Safety
Lipid Peroxidation
Liver
Fats
Body Weight
Insulin
Organ Size
Muscle Proteins
Micronutrients
DNA
Carbohydrate Metabolism
Sugars

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Inorganic Chemistry

Cite this

Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex. / Shara, Michael; Kincaid, Anthony; Limpach, Aimee L.; Sandstrom, Robert W.; Barrett, Laura; Norton, Neil; Bramble, J. D.; Yasmin, Taharat; Tran, Janet; Chatterjee, Archana; Bagchi, Manashi; Bagchi, Debasis.

In: Journal of Inorganic Biochemistry, Vol. 101, No. 7, 07.2007, p. 1059-1069.

Research output: Contribution to journalArticle

Shara, M, Kincaid, A, Limpach, AL, Sandstrom, RW, Barrett, L, Norton, N, Bramble, JD, Yasmin, T, Tran, J, Chatterjee, A, Bagchi, M & Bagchi, D 2007, 'Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex', Journal of Inorganic Biochemistry, vol. 101, no. 7, pp. 1059-1069. https://doi.org/10.1016/j.jinorgbio.2007.03.015
Shara, Michael ; Kincaid, Anthony ; Limpach, Aimee L. ; Sandstrom, Robert W. ; Barrett, Laura ; Norton, Neil ; Bramble, J. D. ; Yasmin, Taharat ; Tran, Janet ; Chatterjee, Archana ; Bagchi, Manashi ; Bagchi, Debasis. / Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex. In: Journal of Inorganic Biochemistry. 2007 ; Vol. 101, No. 7. pp. 1059-1069.
@article{18aeee6591904dcf9850d417928e7448,
title = "Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex",
abstract = "Chromium (III) is an essential micronutrient required for normal protein, fat and carbohydrate metabolism, as well as helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. A broad spectrum of research investigations including in vitro, in vivo and clinical studies demonstrated the beneficial effects of novel oxygen- coordinated niacin-bound chromium (III) complex (NBC) in promoting glucose-insulin sensitivity, lipid profile, cardioprotective ability and lean body mass. This study examined the long-term safety of NBC by orally administering either 0 or 25 ppm or the human equivalency dose of 1000 μg elemental chromium (III) as NBC per day for 52 consecutive weeks to male and female Sprague-Dawley rats. Animals of each group and each gender were sacrificed on 26, 39, or 52 weeks of treatment. Body weight, physical and ocular health, feed and water intake, selected organ weights as such and as a percentage of liver and brain weight, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluations were conducted. At 26, 39, or 52 weeks of treatment, body weight gain was significantly reduced by 7.7{\%}, 8.1{\%} and 14.9{\%} in male rats, and 5.5{\%}, 11.4{\%} and 9.6{\%} in female rats, respectively, in the NBC treatment groups. No significant changes were observed in hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluation between control and NBC groups at these time points. These findings, thus far, are in agreement with the subchronic studies in terms of the safety of NBC.",
author = "Michael Shara and Anthony Kincaid and Limpach, {Aimee L.} and Sandstrom, {Robert W.} and Laura Barrett and Neil Norton and Bramble, {J. D.} and Taharat Yasmin and Janet Tran and Archana Chatterjee and Manashi Bagchi and Debasis Bagchi",
year = "2007",
month = "7",
doi = "10.1016/j.jinorgbio.2007.03.015",
language = "English",
volume = "101",
pages = "1059--1069",
journal = "Journal of Inorganic Biochemistry",
issn = "0162-0134",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex

AU - Shara, Michael

AU - Kincaid, Anthony

AU - Limpach, Aimee L.

AU - Sandstrom, Robert W.

AU - Barrett, Laura

AU - Norton, Neil

AU - Bramble, J. D.

AU - Yasmin, Taharat

AU - Tran, Janet

AU - Chatterjee, Archana

AU - Bagchi, Manashi

AU - Bagchi, Debasis

PY - 2007/7

Y1 - 2007/7

N2 - Chromium (III) is an essential micronutrient required for normal protein, fat and carbohydrate metabolism, as well as helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. A broad spectrum of research investigations including in vitro, in vivo and clinical studies demonstrated the beneficial effects of novel oxygen- coordinated niacin-bound chromium (III) complex (NBC) in promoting glucose-insulin sensitivity, lipid profile, cardioprotective ability and lean body mass. This study examined the long-term safety of NBC by orally administering either 0 or 25 ppm or the human equivalency dose of 1000 μg elemental chromium (III) as NBC per day for 52 consecutive weeks to male and female Sprague-Dawley rats. Animals of each group and each gender were sacrificed on 26, 39, or 52 weeks of treatment. Body weight, physical and ocular health, feed and water intake, selected organ weights as such and as a percentage of liver and brain weight, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluations were conducted. At 26, 39, or 52 weeks of treatment, body weight gain was significantly reduced by 7.7%, 8.1% and 14.9% in male rats, and 5.5%, 11.4% and 9.6% in female rats, respectively, in the NBC treatment groups. No significant changes were observed in hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluation between control and NBC groups at these time points. These findings, thus far, are in agreement with the subchronic studies in terms of the safety of NBC.

AB - Chromium (III) is an essential micronutrient required for normal protein, fat and carbohydrate metabolism, as well as helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. A broad spectrum of research investigations including in vitro, in vivo and clinical studies demonstrated the beneficial effects of novel oxygen- coordinated niacin-bound chromium (III) complex (NBC) in promoting glucose-insulin sensitivity, lipid profile, cardioprotective ability and lean body mass. This study examined the long-term safety of NBC by orally administering either 0 or 25 ppm or the human equivalency dose of 1000 μg elemental chromium (III) as NBC per day for 52 consecutive weeks to male and female Sprague-Dawley rats. Animals of each group and each gender were sacrificed on 26, 39, or 52 weeks of treatment. Body weight, physical and ocular health, feed and water intake, selected organ weights as such and as a percentage of liver and brain weight, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluations were conducted. At 26, 39, or 52 weeks of treatment, body weight gain was significantly reduced by 7.7%, 8.1% and 14.9% in male rats, and 5.5%, 11.4% and 9.6% in female rats, respectively, in the NBC treatment groups. No significant changes were observed in hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluation between control and NBC groups at these time points. These findings, thus far, are in agreement with the subchronic studies in terms of the safety of NBC.

UR - http://www.scopus.com/inward/record.url?scp=34250221472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250221472&partnerID=8YFLogxK

U2 - 10.1016/j.jinorgbio.2007.03.015

DO - 10.1016/j.jinorgbio.2007.03.015

M3 - Article

C2 - 17555823

AN - SCOPUS:34250221472

VL - 101

SP - 1059

EP - 1069

JO - Journal of Inorganic Biochemistry

JF - Journal of Inorganic Biochemistry

SN - 0162-0134

IS - 7

ER -